etintidine and Stomach-Ulcer

Greatly improved understanding of the cellular basis for gastric acid secretion and gastroduodenal mucosal defense has led to a dramatic improvement in the pharmacologic treatment of peptic ulcer disease. The advances produced by cimetidine and ranitidine are being continued by a new generation of histamine receptor antagonists, as well as by other anti-ulcer agents. These new drugs, when used appropriately, will greatly expand the surgeon's ability to treat patients with peptic ulcer disease. A knowledge of the pathophysiologic characteristics of peptic ulceration and of the inherent limitations of each agent will become increasingly important for surgeons who treat these patients.

Topics: Acetylcholine; Benzimidazoles; Chemical Phenomena; Chemistry; Cimetidine; Disease Susceptibility; Dose-Response Relationship, Drug; Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Gastrins; Histamine; Histamine H2 Antagonists; Humans; Imidazoles; Intestinal Mucosa; Peptic Ulcer; Ranitidine; Receptors, Muscarinic; Stimulation, Chemical; Stomach Ulcer